BRAF and neoplasm: Additionally, BRAF inhibitors may downregulate the expression of immune checkpoint molecules on the surface of tumor cells, such as PD-L1, which helps to relieve the immunosuppression imposed by the tumor and enhances the anti-tumor activity of T cells.148